Insight
WHIS 2025: A powerhouse of innovation across the women’s health landscape
The agenda has been unveiled for WHIS 2025.
Formerly the Women’s Health Innovation Summit, this year’s event brings together the entire women’s health ecosystem and incorporates previous FemTech and Reproductive Health events.
A bold move, it consolidates multi-sector efforts to accelerate industry-wide solutions across women’s health, mirroring a critical moment of convergence in women’s health innovation.
View the agenda here: https://whisusa.com/whis-2025/agenda?utm_source=Femtech World&utm_medium=affiliate&utm_campaign=92.7_partnerarticle_agenda
A Unified Approach to Women’s Healthspan
WHIS 2025 unites a diverse range of stakeholders: start-ups and scale-ups, investors, pharmaceutical and biotech multinationals, payers, public sector and regulatory bodies, with service providers like CROs, legal advisors, and consultancy groups.
The event’s mission is clear: tackle persistent disparities by fostering commercial, regulatory, clinical, and technological insight sharing across a comprehensive women’s health agenda.
What’s On and Who’s Talking
- Innovation Showcase: At the beating heart of WHIS, 20 trailblazing start-ups will pitch across two categories – Digital Health & FemTech and Therapeutics & Med Devices – to an audience of 800+ decision-makers
- WHIS Innovators Academy: New in 2025, this pre-event deep-dive day equips emerging companies with mission-critical skills, from IP, branding, and reimbursement, to regulatory fast-tracking, market strategy, and trial recruitment
- Keynotes, Panels and Presentations: Accelerate growth, drive adoption, and deliver measurable outcomes across the entire care spectrum by updating your strategy in line with the latest insights from industry leaders. From unlocking funding pathways and payer strategies, to navigating regulatory hurdles and advancing clinical validation, these sessions are designed to help you supercharge your progress.
- Structured 1:2:1 Networking: Forge commercial collaborations from seed to global distribution attendees by pre-scheduling meetings with the partner that matter most to you.
Why It Matters to the FemTech Community
This event addresses long-standing critical investment signals: reproductive health markets—such as endometriosis management—are now projected to reach into the hundreds of billions annually, a figure amplified by unmet needs and underinvestment.
For FemTech founders and investors, it offers both runway and runway acceleration: showcase opportunities, high-level investor & payer access, coupled with actionable insights on pathways to scale, reimbursement, and regulatory navigation.
Who Attends and Why Their Voice Counts
- Start-ups & SMEs: Will find a launchpad for visibility, partnerships, and funding. The dedicated Innovation Showcase is a proven platform for finalists to attract investment.
- Payers & Providers: Gain early sight of clinical and digital tools that can improve women’s health outcomes while reining in cost drivers, particularly in maternal and chronic care sectors.
- Big Pharma & Biotech: Engage with emerging technologies and pipeline prospects that complement your portfolios and explore acquisition and licensing pathways.
- Service Providers & Policymakers: Exchange regulatory, reimbursement, legal, and market access strategies that support scaling throughout lifespan-focused care.
WHIS 2025 marks a pivotal chapter in women’s health.
By weaving together digital, clinical, commercial, and regulatory threads into one cohesive platform, it offers a rare opportunity for women’s health leaders to not only showcase innovations but to implement them and scale them as we deliver the future of health for women.
Registration is open now, make sure you secure your ticket here: https://kisacoresearch.com/whis-2025/register?utm_source=Femtech World&utm_medium=affiliate&utm_campaign=92.7_partnerarticle_register
Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.
The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.
Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.
Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.
Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.
“This is critical and hopefully can help mothers prepare accordingly.”
The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.
Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.
The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.
The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.
“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.
“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”
The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.
Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.
“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.
“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”
The World Health Organization (WHO) welcomed a delegation of parliamentarians to its Geneva headquarters for a high-level dialogue on women’s health and sexual and reproductive health and rights.
The meeting on 20 January 2026 focused on women’s health, sexual and reproductive health and rights, noncommunicable diseases (long-term conditions such as cancer and diabetes) and global health cooperation.
The exchange was convened by the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, bringing together parliamentarians from Albania, Germany, Georgia, Mexico, Slovakia, South Africa, Sri Lanka, Sweden and Zimbabwe.
A central theme was the need to move beyond fragmented approaches to women’s health.
Dr Alia El-Yassir, WHO director for gender, equity and diversity, highlighted that outcomes are shaped by gender inequalities, social norms and structural barriers across the life course, requiring coordinated action across health systems.
Thirty years after the Beijing Declaration and Platform for Action, a landmark framework adopted in 1995 to advance gender equality and women’s rights, Dr Anna Coates, WHO gender equality technical lead, noted that progress on women’s health remains uneven.
She called for health systems that are more gender-responsive and able to address women’s health holistically across the life course.
Parliamentarians stressed that health is inseparable from wider social and economic policies, and called for stronger links between evidence, legislation and measurable impact at country level.
The meeting also focused on sexual and reproductive health and rights, where parliamentarians expressed interest in engaging on issues that directly affect their constituents.
Dr Pascale Allotey, director of WHO’s Department of Sexual, Reproductive, Maternal, Child, Adolescent Health and Ageing, outlined WHO’s life-course approach to sexual and reproductive health and rights.
She highlighted how needs evolve from birth to older age and how these are shaped by social determinants, humanitarian crises and demographic trends.
Dr Allotey underscored the role of parliamentarians in advancing sexual and reproductive health and rights and the importance of continued engagement with WHO to support evidence-based policy-making.
The agenda highlighted cancer as a growing priority for women’s health and for health system sustainability. Dr Prebo Barango, lead for the Cervical Cancer Elimination Initiative, Dr Meghan Doherty, consultant for palliative care, and Santiago Milan, lead for the WHO Global Platform for Access to Childhood Cancer Medicine, presented WHO’s integrated approach to cancer control.
Palliative care is treatment and support that aims to improve quality of life for people with serious illness by managing pain and other symptoms.
The discussion underlined the need for sustained political commitment and domestic investment to address noncommunicable diseases.
Parliamentarians shared national experiences showing the social and economic impacts of cancer on families and caregivers, reinforcing the importance of improving health literacy, reducing stigma and delivering people-centred care.
The meeting also addressed the state of global multilateralism.
Dr Jeremy Farrar, assistant director-general for health promotion, disease prevention and care, outlined how WHO has restructured to enhance efficiency, impact and capacity to support countries.
He reaffirmed WHO’s commitment to more systematic engagement with parliaments, recognising their role in shaping health policy, legislation and budgets.
The exchange concluded with a call for continued collaboration, including through partnerships with the Konrad-Adenauer-Stiftung and the UNITE Parliamentarians Network for Global Health, ahead of the UNITE Global Summit 2026 on 6–7 March in Manila, the Philippines.
Agilent has FDA approval for a test to identify ovarian cancer patients who may be eligible for immunotherapy.
Agilent’s PD-L1 IHC 22C3 pharmDx is the only FDA-approved companion diagnostic to help identify patients with epithelial ovarian, fallopian tube or primary peritoneal carcinoma whose tumours express PD-L1 and who may be eligible for treatment with KEYTRUDA, Merck’s anti-PD-1 therapy.
A companion diagnostic is a test used alongside a specific treatment to show whether a patient is suitable for that therapy. PD-L1 is a protein on some cancer cells that helps tumours evade the immune system.
These cancers affect the reproductive system and the lining of the abdominal cavity.
The test enables pathologists to assess PD-L1 expression at diagnosis to support treatment decisions in a disease where options remain limited for many.
This is the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA.
Nina Green, vice president and general manager of Agilent’s clinical diagnostics division, said: “Delivering effective precision oncology requires close collaboration between diagnostics and therapeutics, and this FDA approval reflects Agilent’s long-standing industry partnership in companion diagnostics.
“We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy.
“As the first immuno-oncology approval for this disease, this milestone underscores our commitment to advancing precision medicine and expanding access to innovative cancer treatments worldwide.”
PD-L1 expression with this test was evaluated in the KEYNOTE-B96 clinical trial supporting its use to identify patients who may benefit from KEYTRUDA.
In the US, ovarian cancer caused approximately 12,730 deaths in 2025 and the five-year survival rate was 51.6 per cent between 2015 and 2021.
In addition to these cancer types, the test is indicated in the US to help identify patients with non-small cell lung cancer, oesophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, triple-negative breast cancer and gastric or gastro-oesophageal junction adenocarcinoma who may benefit from treatment with KEYTRUDA.
The test was developed by Agilent with Merck as a companion diagnostic for KEYTRUDA.
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Menopause3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now